The aggressiveness of pancreatic adenocarcinoma makes it a deadly disease, with its incidence rate and fatality rate almost equal. Surgery represents the only means to provide cure to patients with pancreatic cancer, though the 5-year survival is less than 10%.
Methods
We review the data on surgical and systemic therapies and provide more details on a newer biologically based medical approach.
Results
Neoadjuvant chemotherapy protocols are confined to one or two institutions, and adjuvant chemotherapy and chemoradiation therapy protocols are far from being standardized. Chemoradiation therapy for locally advanced pancreatic cancer offers limited benefits. Protocols that include gemcitabine and 5-fluorouracil, while comparing favorably to historical controls, offer median survivals at approximately 8 months.
Conclusions
More effective protocols with combinations of approaches agents are needed to improve the treatment of pancreatic cancer.
References
1.
JanesRHJr, NiederhuberJ.E., ChmielJ.S.. Pattern of care for pancreatic cancer: results of a survey by the commission on cancer.Ann Surg.1996; 223: 261–272.
2.
NiederauC., GrendellJ.H.. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers.Pancreas.1992; 7: 66–86.
3.
LinderS., BlasjoM., SundelinP.. Aspects of percutaneous fine-needle aspiration biopsy in the diagnosis of pancreatic carcinoma.Am J Surg.1997; 174: 303–306.
4.
UeharaH., NakaizumiA., BabaM.. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice.Am J Gastroenterol.1996; 91: 1616–1621.
5.
CampmanS.C., FajardoM.A., RipponM.B.. Adenosquamous carcinoma arising in a mucinous cystadenoma of the pancreas.J Surg Oncol.1997; 64: 159–162.
6.
CoiaL., HoffmanJ., ScherR.. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.Int J Radiat Oncol Biol Phys.1994; 30: 161–167.
7.
MillerA.R., RobinsonE.K., LeeJ.E.. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas.Surg Oncol Clin N Am.1998; 7: 183–197.
8.
WaneboH.J., GlicksmanA.S., VezeridisM.P.. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer.Arch Surg.2000; 135: 81–88.
9.
WhiteR., LeeC., AnscherM.. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.Ann Surg Oncol.1999; 6: 38–45.
10.
KalserM.H., EllenbergS.S.. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.Arch Surg.1985; 120: 899–903.
11.
Gastrointestinal Tumor Study Group.Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer.Cancer.1987; 59: 2006–2010.
12.
KlinkenbijlJ.H., SahmoudT., van PelR.. Radiotherapy and 5FU after curative resection of cancer of the pancreas and periampullary region: a phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group.Eur J Cancer.1997; 33: 1239. Abstract.
13.
BakkevoldK.E., ArnesjoB., DahlO.. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater, results of a controlled prospective, randomised multicentre study.Eur J Cancer.1993; 29A: 698–703.
14.
NishimuraY., HosotaniR., ShibamotoY.External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications.Int J Radiat Oncol Biol Phys.1997; 39: 39–49.
15.
LinkK.H., GansaugeF., RilingerN.. Celiac artery adjuvant chemotherapy. Results of a prospective trial.Int J Pancreatol.1997; 21: 65–69.
16.
MoertelC.G., FrytakS., HahnR.G.. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.Cancer.1981; 48: 1705–1710.
17.
MooreM.J., AndersenJ., BurrisH.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.J Clin Oncol.1997; 15: 2403–2413.
18.
HidalgoM., CastellanoD., Paz-AresL.. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.J Clin Oncol.1999; 17: 585–592.
19.
GutzlerF., MoehlerM., HoschW.P.. A phase I study of gem-citabine (GEM) in combination with 5 days 5-fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinomas of pancreas and bile duct.Proc Annu Meet Am Soc Clin Oncol.1999; 18: A1097.
20.
LouvetC., HammelP., AndréT.. Multicenter Phase II study in advanced pancreatic adenocarcinoma patients treated with a combination of leucovorin, 5FU bolus and infusion, and gemcitabine (FOLFUGEM regimen).Proc Annu Meet Am Soc Clin Oncol.1999; A1054.
21.
Menke-PluymersM.B., KlinkenbijlJ.H., TjioeM.. Treatment of locoregional recurrence after intentional curative resection of pancreatic cancer.Hepatogastroenterology.1992; 39: 429–432.
22.
AignerK.R., GailhoferS.. Celiac axis infusion (MMC, CDDP, 5FU) and aortic stop-flow infusion vs abdominal hypoxic perfusion (MMC) in UICC stage II/IV pancreatic cancer: 48 patients.Reg Cancer Treat.1993; 6: 3.
23.
ZervosE.E., ShafiiA.E., RosemurgyA.. Matrix metalloproteinase inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.J Surg Res.1999; 81: 65–68.
24.
ZervosE.E., ShafiiA.E., HaqM.. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro.J Surg Res.1999; 84: 162–167.
25.
ZervosE.E., HaqM., ShafiiA.E.. Matrix-metalloproteinase activity in surgical specimens accurately reflects metastatic potential of human pancreatic cancer.Soc Surg Aliment Tract Proc.1999; A2143.
26.
ZervosE.E., NormanJ.G., GowerW.R.. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo.J Surg Res.1997; 69: 367–371.
27.
ZervosE.E., FranzM.G., SalhabK.. Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.J Gastrointest Surg. In press.
28.
HaqM., ShafiiA., ZervosE.E.. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.Cancer Res. In press.
29.
RosemurgyA., HarrisJ., LanglebenA.. Marimastat in patients with advanced pancreatic cancer: a dose-finding study.Am J Clin Oncol.1999; 22: 247–252.
30.
RosemurgyA., BuckelsJ., CharnleyR.. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer.Proc Annu Meet Am Soc Clin Oncol.1999; A1005.
